Overview
Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life. Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and efficacy since initial FDA approval in 1975. This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.
Background
Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life. Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and efficacy since initial FDA approval in 1975. This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.
Indication
Oxybutynin is indicated for the symptomatic treatment of overactive bladder, which causes urge urinary incontinence and frequency, and urgency. Oxybutynin may also be used for children aged 6 and above for the symptomatic management of detrusor muscle overactivity which has been found to be related to a neurological condition. Spina bifida is an example of a neurological condition in which oxybutynin may be used to control urinary symptoms. On occasion, oxybutynin may be used off-label to relieve bladder spasms associated with ureteral stents or urinary catheters.
Associated Conditions
- Bladder Spasms
- Detrusor Hyperreflexia
- Overactive Bladder Syndrome (OABS)
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2014/06/27 | Phase 4 | Terminated | |||
2014/03/31 | Phase 3 | Withdrawn | |||
2013/10/08 | N/A | Completed | |||
2013/07/15 | Phase 4 | Completed | |||
2013/05/16 | Phase 3 | Completed | |||
2012/10/30 | Phase 3 | Completed | |||
2012/03/19 | Phase 3 | Completed | |||
2011/11/22 | Not Applicable | Completed | Centro de Reabilitação e Readaptação Dr. Henrique Santillo | ||
2011/08/26 | Phase 4 | UNKNOWN | Adana Numune Training and Research Hospital | ||
2011/06/10 | Phase 2 | Completed |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Rising Pharma Holdings, Inc. | 64980-209 | ORAL | 5 mg in 1 1 | 3/29/2022 | |
| Chartwell RX, LLC | 62135-508 | ORAL | 10 mg in 1 1 | 3/6/2023 | |
| Aphena Pharma Solutions - Tennessee, Inc. | 43353-769 | ORAL | 10 mg in 1 1 | 3/26/2012 | |
| Physicians Total Care, Inc. | 54868-4502 | ORAL | 10 mg in 1 1 | 2/16/2012 | |
| Physicians Total Care, Inc. | 54868-5742 | ORAL | 5 mg in 1 1 | 1/21/2010 | |
| Ajanta Pharma USA Inc. | 27241-156 | ORAL | 10 mg in 1 1 | 5/25/2023 | |
| Novitium Pharma LLC | 70954-005 | ORAL | 5 mg in 1 1 | 8/24/2021 | |
| Ajanta Pharma USA Inc. | 27241-157 | ORAL | 15 mg in 1 1 | 5/25/2023 | |
| Physicians Total Care, Inc. | 54868-4835 | ORAL | 15 mg in 1 1 | 2/16/2012 | |
| Bryant Ranch Prepack | 71335-1494 | ORAL | 5 mg in 1 1 | 5/23/2023 |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||